Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

December 13, 2022

https://www.globenewswire.com/news-release/2022/12/13/2572529/0/en/Marker-Therapeutics-and-Lincoln-Park-Capital-Enter-into-a-Common-Stock-Purchase-Agreement-for-up-to-25-Million.html

HOUSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company has entered into a Common Stock Purchase Agreement (the “Agreement”) for up to $25 million with Lincoln Park Capital Fund (“LPC”), a Chicago-based institutional investor and long-term Marker shareholder.

Read more at globenewswire.com

Related news for (MRKR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.